查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014307

细胞疗法市场：按类型、治疗方法、给药途径、应用和最终用户划分－2026-2032年全球市场预测

Cell Therapy Market by Type, Therapy Type, Mode of Administration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，细胞治疗市场价值将达到 105.4 亿美元，到 2026 年将成长到 115.8 亿美元，到 2032 年将达到 225 亿美元，复合年增长率为 11.42%。

主要市场统计数据
基准年 2025 105.4亿美元
预计年份：2026年 115.8亿美元
预测年份 2032 225亿美元
复合年增长率 (%) 11.42%

细胞疗法正迅速崛起为现代生物医学领域最具活力的前沿领域之一，它整合了先进的细胞工程、免疫学和再生医学方法，以满足尚未满足的医疗需求。近年来，科学进展已从概念验证（PoC）阶段迈向日益成熟的临床项目，涵盖自体和异体构建、多种给药方法以及不断扩展的治疗应用。随着技术基础的日益成熟，相关人员如今面临着科学、监管、生产和商业性等诸多因素之间错综复杂的相互作用，这些因素将决定转化研究的成败。

本导言透过聚焦影响专案进度和商业化准备的策略转折点，将读者置于复杂的背景中。它还重点阐述了推动开发人员、服务供应商和临床机构决策的趋同趋势，例如平台标准化、模组化製造和支付方合作。重要的是，本文超越了实验室层面，探讨了实际部署中所面临的挑战，包括供应链韧性、载体生产和病患取得途径。透过从营运角度分析现状，本节旨在帮助领导者评估投资重点、降低风险以及哪些伙伴关係能够加速从临床潜力到永续治疗交付的转换。

变革性的变化正在重塑细胞疗法的格局，而这种变化是由技术突破、不断变化的监管环境、製造技术的进步以及支付方参与度的动态所驱动的。

近年来，细胞治疗领域正经历变革性的转变，这既得益于技术突破，也得益于治疗方法研发流程的系统性变革。基因编辑和模组化生产方法消除了技术瓶颈，实现了治疗方案的迭代优化。同时，监管机构也更积极地采用适应性证据框架，这改变了研发进度，并为有条件的市场准入开闢了新的途径。这些变化共同加速了学习週期，并促进了从早期临床试验到更广泛临床计画的过渡。

2025 年美国关税变化对细胞疗法供应链的累积影响：跨境采购、组件定价和策略采购的考量。

美国2025年实施的关税调整正在对细胞疗法供应链、采购决策和跨国筹资策略产生连锁反应。细胞疗法研发的许多环节都依赖来自世界各地的专用试剂、一次性用品和设备，但关税的调整改变了供应商之间的市场相对竞争力，促使专案团队重新评估其供应商组合。因此，筹资策略正朝着地域多元化和更严格地筛选替代供应商的方向转变，以规避依赖单一供应商的风险。

关键细分洞察揭示了治疗类型、给药途径、临床应用、治疗来源和最终用户如何决定开发平臺和市场进入。

透过市场区隔分析市场发现，不同的研发路径和临床应用案例需要独特的策略方法。依类型划分，市场可分为「非干细胞」和「干细胞」两大类。 「非干细胞」类主要包括CAR-T细胞、树突细胞和自然杀手细胞疗法，每种疗法都有其独特的生产基础设施和临床终点。 「干细胞」类则包括胚胎干细胞、造血干细胞和间质干细胞，每种干细胞都涉及不同的伦理、监管和规模化生产的考量。根据治疗方法来源，疗法可分为同种异体移植和自体移植。自体移植需要针对患者来源的材料建立个人化的供应链和物流，而同种异体移植则专注于大量生产和细胞库保存。

影响美洲、欧洲、中东和非洲以及亚太地区的区域趋势和策略考量，这些因素会影响临床试验地点、製造地和进入。

区域趋势对专案设计、生产策略和市场进入计画有显着影响，美洲、欧洲、中东和非洲以及亚太地区呈现出不同的模式。在美洲，卓越的临床水平和健全的投资生态系统推动先进的临床项目和大规模生产倡议，而监管路径则优先考虑安全性和上市后证据。在欧洲、中东和非洲，跨多个司法管辖区的监管协调以及强大的临床网络促进了跨国临床试验设计和生产方面的合作伙伴关係，但各国报销框架的显着差异可能会影响产品上市的顺序。

来自主要企业的见解，重点关注细胞治疗生态系统中的竞争定位、合作模式、平台专业化和差异化策略。

在整个细胞治疗生态系统中运作的主要企业展现出差异化的策略，这反映了它们各自的核心能力和长期发展目标。大型製药企业通常寻求平台收购和策略合作，以利用其商业基础设施拓展后期产品，并将其细胞治疗能力整合到更广泛的免疫肿瘤学和再生医学产品组合中。同时，纯粹的细胞治疗研发公司则倾向于专注于科学差异化，例如新型工程化构建体或独特的细胞表型，优先考虑转化验证和临床差异化，以确保获得合作伙伴关係和许可协议。

为产业领导者提供切实可行的建议，以加速转化研究、优化供应链、加强与监管机构的合作，并确保永续的商业化路径。

产业领导者应采取一系列切实可行的措施，平衡短期营运需求与长期策略定位。首先，透过设计能够产生与监管机构和支付方均相关的终点指标的临床试验，将研发重点与可操作的证据生成相结合。这种双重关注将加快市场准入谈判，并降低下游谈判风险。其次，透过选择二级供应商、制定区域筹资策略以及考虑采用混合生产结构来降低关税风险和物流脆弱性，从而投资于供应链韧性。

调查方法调查方法方法与资料来源、专家访谈技巧、分析架构与检验过程。

本调查方法结合了结构化证据整合和初步定性研究，以提供可靠且检验的分析结果。此方法首先对公开的科学文献、监管指导文件、临床试验註册资讯和专利趋势进行全面回顾，从而建构对平台技术和临床开发路径的基础性理解。随后，透过对包括开发人员、生产主管、临床研究人员和监管专家在内的专家进行有针对性的访谈，检验了在二次研究中提出的关键主题假设，从而提供了实践背景和前瞻性观点。

在细胞疗法领域，结论是整合，重点强调了相关人员为最大限度地发挥临床和商业性影响而面临的策略挑战、持续挑战和实际途径。

总之，本分析旨在为细胞治疗生态系统中的相关人员提出一个简洁明了的策略挑战。儘管科学进步不断扩大可用治疗方法的范围，但商业性成功越来越依赖生产製造、供应链和支付方参与方面的卓越营运。那些能够将科学差异化与可重复、扩充性的流程以及早期价值验证相结合的机构，将更有能力满足监管要求并确保可持续的市场进入。自体疗法中物流和生产方面的差异以及区域监管碎片化等持续存在的挑战，需要一种结合公私合营和定向投资的协作应对策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 细胞疗法市场：按类型划分

  • 非干细胞
    • CAR-T细胞
    • 树突状细胞
    • NK细胞
  • 干细胞
    • 胚胎干细胞
    • 造血干细胞
    • 间质干细胞

第九章 依治疗方法的细胞疗法市场

  • 同种
  • 自体

第十章：依给药途径分類的细胞疗法市场

  • 肌肉内部
  • 肿瘤内部
  • 静脉

第十一章 细胞疗法市场：依应用领域划分

  • 自体免疫疾病
    • 多发性硬化症
    • 类风湿性关节炎
  • 癌症治疗
    • 骨髓恶性肿瘤
    • 固态肿瘤
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 再生医学

第十二章 细胞疗法市场：依最终用户划分

  • 学术和研究机构
  • 诊所
  • 私人考试机构
  • 医院

第十三章 细胞疗法市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 细胞疗法市集：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 细胞疗法市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国细胞治疗市场

第十七章：中国细胞治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Castle Creek Biosciences, Inc.
  • Catalent, Inc.
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Lonza Group Ltd.
  • Medipost Co., Ltd.
  • Mesoblast Ltd.
  • Novartis AG
  • NuVasive, Inc.
  • Pfizer Inc.
  • Sartorius AG
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • TegoScience
  • Thermo Fisher Scientific, Inc.
  • Vericel Corporation
Product Code: MRR-433AB1DC28D4

The Cell Therapy Market was valued at USD 10.54 billion in 2025 and is projected to grow to USD 11.58 billion in 2026, with a CAGR of 11.42%, reaching USD 22.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.54 billion
Estimated Year [2026] USD 11.58 billion
Forecast Year [2032] USD 22.50 billion
CAGR (%) 11.42%

Cell therapy has emerged as one of the most dynamic frontiers in modern biomedicine, blending advanced cellular engineering, immunology, and regenerative approaches to address unmet clinical needs. Over recent years, scientific progress has migrated from conceptual proof-of-concept work into increasingly sophisticated clinical programs that span autologous and allogenic constructs, diverse modes of administration, and a widening set of therapeutic applications. As the technology stack matures, stakeholders now confront a complex interplay of scientific, regulatory, manufacturing, and commercial forces that shape translational success.

This introduction situates readers within that complexity by focusing on the strategic inflection points that influence program progression and commercial readiness. It emphasizes the convergent trends-platform standardization, modular manufacturing, and payer engagement-that drive decision-making across developers, service providers, and clinical institutions. Importantly, the narrative moves beyond the laboratory to consider real-world implementation challenges, including supply chain resilience, vector production, and patient access pathways. By framing the landscape in operational terms, the section prepares leaders to assess where to concentrate investment, how to mitigate risk, and which partnerships accelerate movement from clinical promise to sustainable therapeutic delivery.

Transformative shifts reshaping the cell therapy landscape driven by technological breakthroughs regulatory evolution manufacturing advances and payer engagement dynamics

Recent years have produced transformative shifts across the cell therapy landscape, driven by both technological breakthroughs and systemic changes in how therapies progress to patients. Gene editing and modular manufacturing approaches have reduced technical bottlenecks and enabled iterative refinement of therapeutic constructs. In parallel, regulatory agencies have signaled greater willingness to engage in adaptive evidence frameworks, which has altered development timelines and opened new pathways for conditional market access. These changes collectively accelerate learning cycles and enable faster translation from early clinical studies into broader clinical programs.

Concurrently, commercialization dynamics have evolved as payers and providers emphasize real-world outcomes and long-term value. This shift compels sponsors to design evidence strategies that extend beyond randomized controlled trials to include registries, pragmatic studies, and health economic models. Manufacturing has also experienced a structural pivot: decentralized and hybrid production models are gaining traction as a response to logistical complexity and regional access challenges. Altogether, these transformative shifts create new opportunities for collaboration between developers, contract manufacturers, clinical centers, and payers, and they demand adaptive strategies that balance scientific ambition with operational scalability.

Cumulative implications of United States tariff changes in 2025 on cell therapy supply chains cross-border sourcing component pricing and strategic procurement considerations

The introduction of tariff changes in the United States in 2025 has exerted a cascading influence on cell therapy supply chains, procurement decisions, and cross-border sourcing strategies. While many components of cell therapy development depend on specialized reagents, disposables, and instrumentation sourced globally, tariffs have altered relative supplier economics and prompted program teams to reassess supplier portfolios. As a result, procurement strategies have shifted toward increased geographic diversification and deeper qualification of alternative suppliers to hedge against single-source exposure.

Operational responses to tariff-induced cost pressures include renegotiating supplier contracts, extending inventory lead times for critical materials, and accelerating localization of upstream activities where feasible. Manufacturing planners have evaluated the trade-off between centralized high-volume production versus regionalized, smaller-scale facilities that reduce tariff and logistics vulnerability. In parallel, clinical trial managers have adapted site selection criteria to factor in potential customs delays and reagent availability, which affects scheduling and patient enrollment pacing. These cumulative effects underscore the need for dynamic supply-chain governance, scenario planning, and proactive regulatory engagement to maintain program continuity and preserve clinical timelines despite external trade policy shifts.

Key segmentation insights revealing how therapeutic type administration route clinical application therapy origin and end users define development pipelines and market access

Deconstructing the market through segmentation reveals how different development pathways and clinical use cases necessitate distinct strategic approaches. When examined by type, the landscape is split between Non-stem Cells and Stem Cells; the Non-stem Cells category prominently includes CAR-T cells, dendritic cells, and natural killer cell programs, each with unique manufacturing footprints and clinical endpoints, while the Stem Cells category comprises embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells, which raise distinct ethical, regulatory, and scale-up considerations. Based on therapy origin, programs cluster into allogenic and autologous modalities, where autologous approaches require personalized supply chains and patient material logistics and allogenic approaches emphasize batch manufacturing and durability of cell banks.

Administration routes further differentiate development and adoption strategies: intramuscular, intratumoral, and intravenous deliveries impose varied clinical workflows, safety monitoring, and formulation stability requirements. Application-driven segmentation highlights pathway-specific needs: autoimmune disorders-such as multiple sclerosis and rheumatoid arthritis-demand chronic treatment models and long-term safety surveillance, whereas cancer treatment programs diverge between hematologic malignancies and solid tumors with corresponding differences in tumor microenvironment challenges and response metrics. Infectious disease applications span bacterial and viral infections with acute treatment timelines and distinct regulatory endpoints. Finally, end users including academic and research institutes, clinics, commercial laboratories, and hospitals each operate within different procurement, infrastructure, and reimbursement environments, which influences adoption speed and post-approval support models. Integrating these segmentation lenses enables more precise alignment of development strategies with clinical, operational, and commercial realities.

Regional dynamics and strategic considerations across Americas Europe Middle East & Africa and Asia-Pacific that influence clinical trial hubs manufacturing sites and access

Regional dynamics exert a powerful influence on program design, manufacturing strategy, and market access planning, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, centers of clinical excellence and a robust investment ecosystem drive advanced clinical programs and large-scale manufacturing initiatives, while regulatory pathways emphasize safety and post-market evidence commitments. In Europe, Middle East & Africa, regulatory harmonization across multiple jurisdictions and strong clinical networks shape multinational trial designs and collaborative manufacturing partnerships, although country-level reimbursement frameworks can vary significantly and influence launch sequencing.

Asia-Pacific presents a diverse range of clinical competencies and manufacturing capabilities, with several countries emerging as regional hubs for both early clinical development and contract manufacturing services; favorable regulatory modernization in some markets has accelerated local trial activity. Across all regions, the interplay between clinical infrastructure, talent availability, and local manufacturing incentives informs decisions on facility placement and trial execution. Moreover, cross-border collaborations, technology transfer agreements, and regional supply routes continue to evolve as stakeholders seek to balance resilience with cost efficiency and patient access imperatives.

Key company insights spotlighting competitive positioning collaboration models platform specialization and competitive differentiation strategies within cell therapy ecosystems

Key companies operating across the cell therapy ecosystem exhibit differentiated strategies that reflect their core capabilities and long-term ambitions. Large pharmaceutical firms often pursue platform acquisition and strategic partnerships to integrate cell therapy capabilities into broader immuno-oncology and regenerative portfolios, leveraging their commercial infrastructure to scale later-stage products. Pure-play cell therapy developers tend to focus on scientific differentiation-such as novel engineering constructs or unique cell phenotypes-and they prioritize translational proof and clinical differentiation to attract partnerships or licensing deals.

Providers of manufacturing and technical services emphasize scalability, quality systems, and supply-chain reliability, positioning themselves as essential enablers for companies that lack in-house production capacity. Tool and reagent suppliers differentiate through proprietary technologies, automation solutions, and validated consumables that reduce process variability. Academic spinouts and research institutes continue to serve as innovation sources, translating basic discoveries into early clinical programs. Across all these actors, collaboration models-ranging from co-development partnerships to fee-for-service arrangements-shape how capabilities are combined. Competitive differentiation increasingly hinges on demonstrated manufacturing reproducibility, regulatory readiness, and the ability to generate robust real-world evidence post-approval.

Actionable recommendations for industry leaders to accelerate translation optimize supply chains enhance regulatory engagement and secure sustainable commercial pathways

Industry leaders should pursue a set of pragmatic, actionable moves that balance near-term operability with long-term strategic positioning. First, align R&D priorities with pragmatic evidence generation by designing trials that produce both regulatory and payer-relevant endpoints; this dual focus accelerates market access discussions and reduces downstream negotiation risk. Next, invest in supply-chain resilience by qualifying secondary suppliers, developing regional sourcing strategies, and examining hybrid manufacturing footprints that reduce tariff exposure and logistical vulnerability.

Leaders must also prioritize regulatory engagement early and continuously, leveraging scientific advice and adaptive regulatory pathways to de-risk pivotal development steps and to clarify post-approval evidence commitments. Strategic partnerships merit active pursuit: form alliances with contract manufacturers, clinical networks, and technology providers to accelerate capacity build-out while preserving capital efficiency. Additionally, embed health economics and outcomes research into development plans to demonstrate value to payers and health systems; early modeling and real-world data capture will inform pricing and reimbursement strategies. Finally, cultivate operational excellence through investment in automation, digital tracking of chain-of-identity, and workforce training programs that reduce variability and accelerate time-to-patient across both autologous and allogenic programs.

Research methodology and evidence synthesis explaining data sources expert consultation methods analytical frameworks and validation processes used to build the analysis

The research methodology combines a structured evidence synthesis with primary qualitative engagement to deliver a robust, validated analysis. The approach began with a comprehensive review of publicly available scientific literature, regulatory guidance documents, clinical trial registries, and patent landscapes to develop a foundational understanding of platform technologies and clinical trajectories. This secondary research established key thematic hypotheses that were then tested through targeted expert consultations, including interviews with developers, manufacturing executives, clinical investigators, and regulatory specialists to obtain operational context and forward-looking perspectives.

Analytical frameworks employed include supply-chain mapping to identify chokepoints, segmentation analysis to align program strategy with clinical use cases, and scenario planning to assess policy and trade impacts. Findings were cross-checked through triangulation of evidence sources and validated in workshops with subject-matter experts to ensure practical relevance and to refine recommendations. Throughout, the process emphasized transparency of assumptions, traceability of evidence, and an iterative validation loop that incorporated stakeholder feedback to improve accuracy and applicability of the insights.

Concluding synthesis highlighting strategic imperatives persistent challenges and pragmatic pathways for stakeholders to maximize clinical and commercial impact in cell therapy

The conclusion synthesizes the analysis into a concise set of strategic imperatives for stakeholders across the cell therapy ecosystem. Scientific momentum continues to expand the range of viable therapeutic constructs, yet commercial success increasingly depends on operational excellence across manufacturing, supply chain, and payer engagement. Organizations that couple scientific differentiation with reproducible, scalable processes and early value demonstration will be better positioned to navigate regulatory expectations and secure durable market access. Persistent challenges-such as logistics for autologous therapies, manufacturing variability, and regional regulatory fragmentation-require coordinated response strategies that blend public-private collaboration with targeted investments.

Looking ahead, the ecosystem will reward adaptive organizations that embrace modular production models, invest in digital infrastructure for chain-of-identity and outcomes capture, and proactively engage payers to design evidence packages that reflect real-world performance. By integrating these strategic priorities with disciplined execution, stakeholders can accelerate patient access while managing the operational complexities inherent to advanced cell-based therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Therapy Market, by Type

  • 8.1. Non-stem Cells
    • 8.1.1. CAR-T Cells
    • 8.1.2. Dendritic Cells
    • 8.1.3. NK Cells
  • 8.2. Stem Cells
    • 8.2.1. Embryonic Stem Cells
    • 8.2.2. Hematopoietic Stem Cell
    • 8.2.3. Mesenchymal Stem Cell

9. Cell Therapy Market, by Therapy Type

  • 9.1. Allogenic
  • 9.2. Autologous

10. Cell Therapy Market, by Mode of Administration

  • 10.1. Intramuscular
  • 10.2. Intratumoral
  • 10.3. Intravenous

11. Cell Therapy Market, by Application

  • 11.1. Autoimmune Disorders
    • 11.1.1. Multiple Sclerosis
    • 11.1.2. Rheumatoid Arthritis
  • 11.2. Cancer Treatment
    • 11.2.1. Hematologic Malignancies
    • 11.2.2. Solid Tumors
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial Infections
    • 11.3.2. Viral Infections
  • 11.4. Regenerative Medicine

12. Cell Therapy Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Clinics
  • 12.3. Commercial Laboratories
  • 12.4. Hospitals

13. Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell Therapy Market

17. China Cell Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anterogen Co., Ltd.
  • 18.6. Astellas Pharma Inc.
  • 18.7. Athersys, Inc.
  • 18.8. BioNTech SE
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Castle Creek Biosciences, Inc.
  • 18.11. Catalent, Inc.
  • 18.12. FUJIFILM Holdings Corporation
  • 18.13. Gilead Sciences, Inc.
  • 18.14. JCR Pharmaceuticals Co., Ltd.
  • 18.15. Kolon TissueGene, Inc.
  • 18.16. Lonza Group Ltd.
  • 18.17. Medipost Co., Ltd.
  • 18.18. Mesoblast Ltd.
  • 18.19. Novartis AG
  • 18.20. NuVasive, Inc.
  • 18.21. Pfizer Inc.
  • 18.22. Sartorius AG
  • 18.23. Stemedica Cell Technologies, Inc.
  • 18.24. Stempeutics Research Pvt. Ltd.
  • 18.25. Takeda Pharmaceutical Company Limited
  • 18.26. TegoScience
  • 18.27. Thermo Fisher Scientific, Inc.
  • 18.28. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)